Skip to main content
Premium Trial:

Request an Annual Quote

OncoDNA, Kura Oncology Sign Patient Enrollment Pact

NEW YORK (GenomeWeb) – OncoDNA announced today that it has signed an agreement to provide patient-enrollment services for on ongoing clinical study of Kura Oncology's head and neck squamous cell carcinoma (HNSCC) drug tipifarnib.

Tipifarnib is a protein farnesyl transferase inhibitor originally developed by Johnson & Johnson for a variety of cancers. Kura acquired the oncology rights to the drug in 2015 and is currently testing it in Phase II trials for HNSCC with HRAS mutations, peripheral T cell lymphoma, myelodysplastic syndromes, and chronic myelomonocytic leukemia.

Under the terms of the deal, OncoDNA will help Kura screen for HRAS-mutant HNSCC patients at study sites, as well as support its recruitment efforts by informing physicians with eligible HNSCC patients about potential treatment and clinical trial options.

Additional terms were not disclosed.

"This agreement is in line with our strategy of collaborating with biopharmaceutical companies," OncoDNA CEO Jean-Pol Detiffe said in a statement. "As we develop our business through Europe and beyond, collaborations such as these demonstrate our ability to assist biopharmaceutical companies with their drug-development programs and support the push towards better patient care."

Earlier this month, OncoDNA inked a similar patient-enrollment services deal with BioClin Therapeutics.

The Scan

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.

Algorithm Teases Out Genetic Ancestry in Individuals at Biobank Scale

Researchers develop an algorithm known as Rye to tease apart ancestry fractions in admixed individuals at a biobank-scale, applying it to 488,221 UK Biobank participants in Nucleic Acids Research.